天津医药 ›› 2023, Vol. 51 ›› Issue (2): 118-123.doi: 10.11958/20220899
收稿日期:
2022-06-09
修回日期:
2022-08-23
出版日期:
2023-02-15
发布日期:
2023-02-24
作者简介:
黄昱刚(1974),男,副主任医师,主要从事呼吸内科方面研究。E-mail:基金资助:
HUANG Yugang1(), TAN Lingjuan1, CHEN Guang2
Received:
2022-06-09
Revised:
2022-08-23
Published:
2023-02-15
Online:
2023-02-24
黄昱刚, 谭伶娟, 陈广. 羽扇豆醇调控miR-100-5p对非小细胞肺癌NCI-H1299细胞生物学行为的影响[J]. 天津医药, 2023, 51(2): 118-123.
HUANG Yugang, TAN Lingjuan, CHEN Guang. Effects of lupeol on the biological behavior of non-small cell lung cancer NCI-H1299 cells by regulating miR-100-5p[J]. Tianjin Medical Journal, 2023, 51(2): 118-123.
摘要:
目的 探讨羽扇豆醇调控miR-100-5p对非小细胞肺癌(NSCLC)NCI-H1299细胞增殖、迁移和侵袭的影响。方法 将体外培养的NCI-H1299细胞分为正常对照(NC)组(未处理)、低剂量组(12.5 μmol/L羽扇豆醇)、中剂量组(25 μmol/L羽扇豆醇)、高剂量组(50 μmol/L羽扇豆醇)、miR-NC组(转染miR-NC)、miR-100-5p组(转染miR-100-5p)、anti-miR-NC+高剂量组(转染anti-miR-NC后用50 μmol/L羽扇豆醇处理)、anti-miR-100-5p+高剂量组(转染anti-miR-100-5p后用50 μmol/L羽扇豆醇处理)。CCK-8和克隆形成实验检测NCI-H1299细胞增殖;Transwell法检测NCI-H1299细胞迁移和侵袭。荧光定量PCR(qPCR)检测miR-100-5p表达;Western blot检测细胞周期蛋白D1(CyclinD1)、基质金属蛋白酶(MMP)2和MMP9蛋白的表达。结果 与NC组比较,低、中、高剂量组NCI-H1299细胞活力、细胞克隆数、迁移数、侵袭数、CyclinD1、MMP2和MMP9蛋白表达降低(P<0.05),miR-100-5p表达逐渐升高(P<0.05)。与miR-NC组比较,miR-100-5p组miR-100-5p表达升高,NCI-H1299细胞活力、细胞克隆数、迁移数、侵袭数、CyclinD1、MMP2和MMP9蛋白表达降低(P<0.05);与anti-miR-NC+高剂量组比较,anti-miR-100-5p+高剂量组miR-100-5p表达下降,NCI-H1299细胞活力、细胞克隆数、迁移数、侵袭数、CyclinD1、MMP2和MMP9蛋白表达升高(P<0.05)。结论 羽扇豆醇通过上调miR-100-5p表达抑制NSCLC细胞NCI-H1299增殖、迁移和侵袭。
中图分类号:
组别 | OD450 | 细胞克隆数(个) | CyclinD1 |
---|---|---|---|
NC组 | 1.01±0.10 | 113.00±8.26 | 0.85±0.09 |
低剂量组 | 0.90±0.09a | 84.00±7.15a | 0.73±0.07a |
中剂量组 | 0.73±0.07ab | 61.00±5.13ab | 0.53±0.05ab |
高剂量组 | 0.51±0.05abc | 50.00±4.02abc | 0.41±0.04abc |
F | 67.047** | 172.777** | 81.965** |
表1 各组NCI-H1299细胞增殖和CyclinD1蛋白表达水平比较 (n=9,$\bar{x}±s$)
Tab.1 Comparison of proliferation and expression level of CyclinD1 protein in NCI-H1299 cells between four groups
组别 | OD450 | 细胞克隆数(个) | CyclinD1 |
---|---|---|---|
NC组 | 1.01±0.10 | 113.00±8.26 | 0.85±0.09 |
低剂量组 | 0.90±0.09a | 84.00±7.15a | 0.73±0.07a |
中剂量组 | 0.73±0.07ab | 61.00±5.13ab | 0.53±0.05ab |
高剂量组 | 0.51±0.05abc | 50.00±4.02abc | 0.41±0.04abc |
F | 67.047** | 172.777** | 81.965** |
组别 | 细胞迁移数(个) | 细胞侵袭数(个) | MMP2 | MMP9 |
---|---|---|---|---|
NC组 | 154.00±12.25 | 136.00±13.32 | 0.83±0.08 | 0.75±0.06 |
低剂量组 | 127.00±10.13a | 101.00±10.03a | 0.70±0.07a | 0.62±0.06a |
中剂量组 | 100.00±9.24ab | 88.00±8.02ab | 0.57±0.05ab | 0.48±0.04ab |
高剂量组 | 62.00±5.16abc | 51.00±4.01abc | 0.42±0.04abc | 0.37±0.03abc |
F | 152.245** | 123.809** | 72.156** | 101.567** |
表2 各组NCI-H1299细胞迁移、侵袭及MMP2、MMP9蛋白表达水平比较 (n=9,$\bar{x}±s$)
Tab.2 Comparison of migration and invasion of NCI-H1299 cells and the expression levels of MMP2 and MMP9 proteins between four groups
组别 | 细胞迁移数(个) | 细胞侵袭数(个) | MMP2 | MMP9 |
---|---|---|---|---|
NC组 | 154.00±12.25 | 136.00±13.32 | 0.83±0.08 | 0.75±0.06 |
低剂量组 | 127.00±10.13a | 101.00±10.03a | 0.70±0.07a | 0.62±0.06a |
中剂量组 | 100.00±9.24ab | 88.00±8.02ab | 0.57±0.05ab | 0.48±0.04ab |
高剂量组 | 62.00±5.16abc | 51.00±4.01abc | 0.42±0.04abc | 0.37±0.03abc |
F | 152.245** | 123.809** | 72.156** | 101.567** |
组别 | miR-100-5p | OD值 | 细胞克隆数(个) | 细胞迁移数(个) | 细胞侵袭数(个) | CyclinD1 | MMP2 | MMP9 |
---|---|---|---|---|---|---|---|---|
miR-NC组 | 1.01±0.11 | 1.09±0.08 | 109.00±11.21 | 152.00±13.01 | 145.00±13.12 | 0.79±0.04 | 0.82±0.07 | 0.72±0.08 |
miR-100-5p组 | 2.68±0.34 | 0.69±0.08 | 56.00±4.12 | 85.00±6.33 | 68.00±5.11 | 0.52±0.06 | 0.56±0.07 | 0.45±0.06 |
t | 14.020** | 10.607** | 13.313** | 13.893** | 16.406** | 11.233** | 7.879** | 8.100** |
表3 过表达miR-100-5p后2组NCI-H1299细胞增殖、迁移和侵袭及CyclinD1、MMP2、MMP9蛋白表达水平比较 (n=9,$\bar{x}±s$)
Tab.3 Comparison of proliferation, migration, invasion and the expression levels of CyclinD1, MMP2 and MMP9 proteins in NCI-H1299 cells between two groups after overexpression of miR-100-5p
组别 | miR-100-5p | OD值 | 细胞克隆数(个) | 细胞迁移数(个) | 细胞侵袭数(个) | CyclinD1 | MMP2 | MMP9 |
---|---|---|---|---|---|---|---|---|
miR-NC组 | 1.01±0.11 | 1.09±0.08 | 109.00±11.21 | 152.00±13.01 | 145.00±13.12 | 0.79±0.04 | 0.82±0.07 | 0.72±0.08 |
miR-100-5p组 | 2.68±0.34 | 0.69±0.08 | 56.00±4.12 | 85.00±6.33 | 68.00±5.11 | 0.52±0.06 | 0.56±0.07 | 0.45±0.06 |
t | 14.020** | 10.607** | 13.313** | 13.893** | 16.406** | 11.233** | 7.879** | 8.100** |
图9 Transwell检测抑制miR-100-5p表达对羽扇豆醇干预后NCI-H1299细胞迁移、侵袭的影响
Fig.9 Effects of inhibition of miR-100-5p expression on migration and invasion of NCI-H1299 cells after lupeol intervention detected by Transwell
组别 | miR-100-5p | OD值 | 细胞克隆数(个) | 细胞迁移数(个) | 细胞侵袭数(个) | CyclinD1 | MMP2 | MMP9 |
---|---|---|---|---|---|---|---|---|
anti-miR-NC+高剂量组 | 1.00±0.09 | 0.58±0.05 | 64.00±5.34 | 47.00±4.34 | 44.00±3.83 | 0.42±0.04 | 0.40±0.03 | 0.35±0.03 |
anti-miR-100-5p+高剂量组 | 0.45±0.04 | 1.12±0.10 | 132.00±9.14 | 77.00±6.54 | 70.00±5.28 | 0.87±0.07 | 0.82±0.07 | 0.76±0.07 |
t | 16.753** | 14.490** | 19.271** | 11.466** | 11.958** | 16.745** | 16.545** | 16.151** |
表4 抑制miR-100-5p表达后2组NCI-H1299细胞增殖、迁移和侵袭及CyclinD1、MMP2、MMP9蛋白表达水平比较 (n=9,$\bar{x}±s$)
Tab.4 Comparison of proliferation, migration and invasion of NCI-H1299 cells and the expression levels of CyclinD1, MMP2, MMP9 proteins between two groups after inhibition of miR-100-5p
组别 | miR-100-5p | OD值 | 细胞克隆数(个) | 细胞迁移数(个) | 细胞侵袭数(个) | CyclinD1 | MMP2 | MMP9 |
---|---|---|---|---|---|---|---|---|
anti-miR-NC+高剂量组 | 1.00±0.09 | 0.58±0.05 | 64.00±5.34 | 47.00±4.34 | 44.00±3.83 | 0.42±0.04 | 0.40±0.03 | 0.35±0.03 |
anti-miR-100-5p+高剂量组 | 0.45±0.04 | 1.12±0.10 | 132.00±9.14 | 77.00±6.54 | 70.00±5.28 | 0.87±0.07 | 0.82±0.07 | 0.76±0.07 |
t | 16.753** | 14.490** | 19.271** | 11.466** | 11.958** | 16.745** | 16.545** | 16.151** |
[1] | LIU K, ZHANG X, XIE L, et al. Lupeol and its derivatives as anticancer and anti-inflammatory agents:Molecular mechanisms and therapeutic efficacy[J]. Pharmacol Res, 2021, 164:105373. doi:10.1016/j.phrs.2020.105373. |
[2] | ZHONG J, HE C, XU F, et al. Lupeol inhibits osteosarcoma progression by up-regulation of HMGA2 via regulating miR-212-3p[J]. J Orthop Surg Res, 2020, 15(1):374. doi:10.1186/s13018-020-01879-0. |
[3] | ZHANG X, GAO Z, CHEN K, et al. Lupeol inhibits the proliferation and migration of MDA-MB-231 breast cancer cells via a novel crosstalk mechanism between autophagy and the EMT[J]. Food Funct, 2022, 13(9):4967-4976. doi:10.1039/d2fo00483f. |
[4] | 刘博佳, 宁青, 钟荣玲, 等. 羽扇豆醇对人肝癌细胞HepG2和SK-HEP-1侵袭、转移的影响及机制研究[J]. 中国中药杂志, 2020, 45(24):6028-6035. |
LIU B J, NING Q, ZHONG R L, et al. Effect of lupeol on invasion and metastasis of human hepatoma HepG2 and SK-HEP-1 cells and its mechanism[J]. Chin J Chin Mat Med, 2020, 45(24):6028-6035. doi:10.19540/j.cnki.cjcmm.20200901.403. | |
[5] | BHATT M, PATEL M, ADNAN M, et al. Anti-metastatic effects of lupeol via the inhibition of MAPK/ERK pathway in lung cancer[J]. Anticancer Agents Med Chem, 2021, 21(2):201-206. doi:10.2174/1871520620666200424131548. |
[6] | MIN T R, PARK H J, HA K T, et al. Suppression of EGFR/STAT3 activity by lupeol contributes to the induction of the apoptosis of human non‑small cell lung cancer cells[J]. Int J Oncol, 2019, 55(1):320-330. doi:10.3892/ijo.2019.4799. |
[7] | TAKAO K, KONISHI H, MATSUBARA D, et al. MiR-3663-3p inhibits the progression of gastric cancer through the CCND1 pathway[J]. Anticancer Res, 2021, 41(5):2441-2449. doi:10.21873/anticanres.15019. |
[8] | GAO S, SHI P, TIAN Z, et al. Overexpression of miR-1225 promotes the progression of breast cancer, resulting in poor prognosis[J]. Clin Exp Med, 2021, 21(2):287-296. doi:10.1007/s10238-020-00676-7. |
[9] | 何剑营, 黄燕燕, 陈志军, 等. 微小RNA-96靶向叉头框转录因子O1促进肺癌细胞增殖和迁移[J]. 中华实验外科杂志, 2020, 37(12):2259-2261. |
HE J Y, HUANG Y Y, CHEN Z J, et al. MicroRNA-96 promotes the proliferation and migration of lung cancer cells by targeting forkhead box O1[J]. Chin J Exp Surg, 2020, 37(12):2259-2261. doi:10.3760/cma.j.cn421213-20190513-00349. | |
[10] | SHEN Y Y, CUI J Y, YUAN J, et al. MiR-451a suppressed cell migration and invasion in non-small cell lung cancer through targeting ATF2[J]. Eur Rev Med Pharmacol Sci, 2018, 22(17):5554-5561. doi:10.26355/eurrev_201809_15818. |
[11] | 李晓君, 江娟, 冯红刚, 等. miR-100-5p通过靶向FGFR3抑制非小细胞肺癌细胞迁移、侵袭和糖酵解[J]. 局解手术学杂志, 2021, 30(5):369-376. |
LI X J, JIANG J, FENG H G, et al. miR-100-5 p inhibiting non-small cell lung cancer cell migration,invasion and glycolysis by targeting FGFR3[J]. Journal of Local Surgery, 2021, 30(5):369-376. doi:10.11659/jjssx.08E020098. | |
[12] | AI L, YI W, CHEN L, et al. Xian-Ling-Gu-Bao protects osteoporosis through promoting osteoblast differentiation by targeting miR-100-5p/KDM6B/RUNX2 axis[J]. In Vitro Cell Dev Biol Anim, 2021, 57(1):3-9. doi:10.1007/s11626-020-00530-w. |
[13] | PRASAD N, SABARWAL A, YADAV U, et al. Lupeol induces S-phase arrest and mitochondria-mediated apoptosis in cervical cancer cells[J]. J Biosci, 2018, 43(2):249-261. |
[14] | 王明, 崔红霞, 刘吉成. 羽扇豆醇增强对沉默ST3GalⅢ基因的MDA-MB-231细胞侵袭转移的抑制作用[J]. 解剖学报, 2020, 51(1):26-31. |
WANG M, CUI H X, LIU J C. Enhancing effect of Lupeol on migration and invasion abilities of ST3GalⅢ-silenced MDA-MB-231 cells[J]. Acta Anatomica Sinica, 2020, 51(1):26-31. doi:10.16098/j.issn.0529-1356.2020.01.005. | |
[15] | 李会荣, 钟秀, 王江川, 等. miR-140-5 p通过调控Wnt1通路对非小细胞肺癌迁移与侵袭能力的影响[J]. 中国免疫学杂志, 2021, 37(2):186-190,200. |
LI H R, ZHONG X, WANG J C, et al. Effect of miR-140-5 p on migration and invasion of non-small cell lung cancer by regulating Wnt1 pathway[J]. Chin J Immunology, 2021, 37(2):186-190,200. doi:10.3969/j.issn.1000-484X.2021.02.011. | |
[16] | TONG R, ZHANG J, WANG C, et al. Inhibition of miR-574-5p suppresses cell growth and metastasis and enhances chemosensitivity by targeting RNA binding protein QKI in cervical cancer cells[J]. Naunyn Schmiedebergs Arch Pharmacol, 2020, 393(6):951-966. doi:10.1007/s00210-019-01772-6. |
[17] | CHEN B, ZHENG S, JIANG F. miR-1293 acts as a tumor promotor in lung adenocarcinoma via targeting phosphoglucomutase 5[J]. PeerJ, 2021, 9:e12140. doi:10.7717/peerj.12140. |
[18] | TAO Y, ZHAN S, WANG Y, et al. Baicalin,the major component of traditional Chinese medicine Scutellaria baicalensis induces colon cancer cell apoptosis through inhibition of oncomiRNAs[J]. Sci Rep, 2018, 8(1):14477. doi:10.1038/s41598-018-32734-2. |
[19] | 张小鹰, 何金花, 王浩, 等. 羽扇豆醇联合miR-145-5p对前列腺癌细胞增殖与凋亡的影响[J]. 中国病理生理杂志, 2020, 36(8):1413-1421. |
ZHANG X Y, HE J H, WANG H, et al. Effects of lupeol and miR-145-5p on proliferation and apoptosis of prostate carcinoma cells[J]. Chin J Pathol, 2020, 36(8):1413-1421. doi:10.3969/j.issn.1000-4718.2020.08.010. | |
[20] | ZHANG H, YANG K, REN T, et al. miR-100-5p inhibits malignant behavior of chordoma cells by targeting IGF1R[J]. Cancer Manag Res, 2020, 12:4129-4137. doi:10.2147/CMAR.S252185. |
[21] | 叶芸, 李苏亮, 袁小华, 等. miR-100-5p下调mTOR抑制前列腺癌细胞的增殖、迁移与侵袭[J]. 山西医科大学学报, 2020, 51(5):376-381. |
YE Y, LI S L, YUAN X H, et al. The miR-100-5p inhibits proliferation,migration and invasion of prostate cancer cells by down-regulating mTOR[J]. J Shanxi Med Univ, 2020, 51(5):376-381. doi:10.13753/j.issn.1007-6611.2020.05.004. |
[1] | 张晋玮, 王燕, 王通. miR-107对口腔鳞癌细胞系CAL27增殖、侵袭及迁移的影响[J]. 天津医药, 2024, 52(9): 897-899. |
[2] | 马佳佳, 张亚苹, 杨斌, 赵美琪, 蒋璐, 黄小玉, 范路畅, 王凤梅. ATOX1通过JAK2/STAT3通路促进肝癌细胞生物学行为的机制探讨[J]. 天津医药, 2024, 52(9): 907-912. |
[3] | 肖小丽, 谢瑶, 龙志. 丙型肝炎患者血清miR-155、miR-205-5p水平变化及诊断价值[J]. 天津医药, 2024, 52(9): 967-970. |
[4] | 霍晶辰, 王悦, 李华, 邱嵘, 苏景伟, 王卓凡, 杨洁. 系统免疫炎症指数对根治性放疗Ⅲ期肺鳞癌患者长期生存的预测价值[J]. 天津医药, 2024, 52(6): 634-638. |
[5] | 刘丹阳, 李永涛, 张海燕, 李林, 刘洋, 沈雷. 乳腺癌细胞条件培养基对骨髓间充质干细胞生物学行为的影响[J]. 天津医药, 2024, 52(5): 454-458. |
[6] | 秦爱英, 陈静, 单风晓, 陆翰杰, 武阳. 非小细胞肺癌组织LncRNA MIR503HG、Wnt1表达与患者术后5年内生存的相关性[J]. 天津医药, 2024, 52(4): 403-408. |
[7] | 徐丹, 刘夏, 钟殿胜. 佐利替尼一线治疗EGFR突变NSCLC伴中枢神经系统转移2例报告[J]. 天津医药, 2024, 52(3): 315-318. |
[8] | 王鑫瑶, 杨惠, 李冰冰. 间充质干细胞在子宫内膜异位症中的研究进展[J]. 天津医药, 2024, 52(2): 215-219. |
[9] | 缪春波, 许迎春, 常以芳. 根皮苷通过下调miR-125a-5p减轻缺氧/复氧诱导的H9C2细胞氧化应激和凋亡[J]. 天津医药, 2024, 52(12): 1233-1238. |
[10] | 林瑶, 刘从娜, 王世霞, 张志勇. 金合欢素调节HMGB1/TLR4信号通路对脂多糖诱导牙髓细胞凋亡的影响[J]. 天津医药, 2024, 52(12): 1238-1243. |
[11] | 张贵婷, 何超. oxLDL/β2GPⅠ/aβ2GPⅠ复合物通过TLR4/MyD88/NF-κB途径促进血管内皮细胞血管生成[J]. 天津医药, 2024, 52(11): 1131-1136. |
[12] | 郝凯凯, 王晓敏, 刘峥, 刘东洋, 李静. 藁本内酯调节RhoA/ROCK信号通路对食管癌细胞生物学行为的影响[J]. 天津医药, 2024, 52(11): 1164-1170. |
[13] | 吴美娜, 戴为正, 潘毓敦, 傅懋林, 陈晓瑜. 常规脑电图联合血清miR-146a、miR-129-5p水平检测对药物难治性癫痫的临床诊断价值[J]. 天津医药, 2024, 52(11): 1207-1210. |
[14] | 孙创新, 李刚. NID1在肾透明细胞癌血管生成中的作用研究[J]. 天津医药, 2024, 52(10): 1009-1013. |
[15] | 徐桂颖, 李玉, 李雪, 刘怡萌, 陈怀永. 气道类器官研究哮喘中Lkb1调控上皮再生的机制[J]. 天津医药, 2024, 52(1): 11-15. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||